Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 7, No 3 (2011) COSTS OF THE HEALTH CARE IN RUSSIA ASSOCIATED WITH SMOKING Abstract  similar documents
A. V. Kontsevaya, A. M. Kalinina
"... total costs of the health care system associated with smoking exceeded RUR 35.8 bln. It corresponded ..."
 
Vol 14, No 1 (2018) SMOKING AS A RISK FACTOR FOR CARDIOVASCULAR AND CEREBROVASCULAR DISEASES: PREVALENCE, IMPACT ON PROGNOSIS, POSSIBLE SMOKING CESSATION STRATEGIES AND THEIR EFFECTIVENESS. Part 2. Advantages of quitting smoking. Strategies to quit smoking Abstract  similar documents
O. D. Ostroumova, I. I. Kopchjonov, T. F. Guseva
"... who continue to smoke. Smoking cessation is the most cost-effective strategy of cardiovascular disease ..."
 
Vol 8, No 3 (2012) PHARMACOECONOMIC ASPECTS OF NICOTINE ADDICTION TREATMENT IN PATIENTS WITH ANGINA REQUIRING CARDIAC SURGERY Abstract  similar documents
A. V. Rudakova, M. S. Berezhnova
"... Smoking is a major risk factor in patients with angina pectoris. Interventions that facilitate ..."
 
Vol 1, No 1 (2005) DRUGS AND SMOKING Abstract  similar documents
J. V. Lukina
"... Smoking is a well – known risk factor of many diseases. It influences the efficacy and safety ..."
 
Vol 13, No 6 (2017) SMOKING AS A RISK FACTOR OF CARDIOVASCULAR AND CEREBROVASCULAR DISEASES: PREVALENCE, IMPACT ON PROGNOSIS, POSSIBLE SMOKING CESSATION STRATEGIES AND THEIR EFFECTIVENESS. Part 1. Smoking Prevalence and Impact on Prognosis Abstract  similar documents
O. D. Ostroumova, A. A. Izvekov, N. Yu. Voevodina
"... The prevalence of smoking in the Russian Federation is 27.7%. Losses of potential years of life ..."
 
Vol 9, No 3 (2013) NICOTINE REPLACEMENT THERAPY OF THE TOBACCO ADDICTION IN PREVENTION OF CARDIORESPIRATORY DISEASES Abstract  similar documents
M. G. Gambaryan
"... of cardiorespiratory diseases. Smoking cessation is the most cost-effective measure for prevention of cardiovascular ..."
 
Vol 7, No 4 (2011) METHODS OF ASSISTANCE FOR SMOKING CESSATION IN INTERNATIONAL CLINICAL RECOMMENDATIONS FOR TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASE Abstract  similar documents
M. S. Berezhnova
"... A review of international recommendations, including methods to assist in smoking cessation ..."
 
Vol 9, No 4 (2013) VARENICLINE IN PATIENTS WITH CARDIOVASCULAR DISEASES – FRIEND OR ENEMY? Abstract  similar documents
Yu. V. Lukina, S. Yu. Martsevich
"... for pharmacotherapy of nicotine addiction due to its high efficacy and advantages of smoking cessation. However ..."
 
Vol 12, No 4 (2016) The implementation of health care aimed at the cessation of tobacco use, treatment of tobacco dependence and consequences of tobacco consumption in the Russian Federation Abstract  similar documents
S. A. Boytsov, P. K. Yablonskiy, M. G. Gambaryan, O. A. Sukhovskaya, O. M. Drapkina
 
Vol 1, No 1 (2005) TOBACCO DEPENDENCE TREATMENT WITH NICOTINE REPLACEMENT THERAPY AS ONE OF THE METHODS FOR CARDIOVASCULAR DISEASE RISK REDUCTION Abstract  similar documents
O. V. Vikhireva, S. A. Shalnova, A. D. Deev
"... to quit smoking. To assess expected reduction of cardiovascular disease (CVD) and total mortality relative ..."
 
Vol 7, No 5 (2011) ANALYSIS OF DIRECT COSTS ASSOCIATED WITH THE USE OF WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION Abstract  similar documents
Yu. B. Belousov, I. S. Yavelov, D. Yu. Belousov, E. V. Afanasieva
"... .98 RUR (in the consequent years), respectively. Conclusion. The cost of warfarin, regardless of the INR ..."
 
Vol 6, No 1 (2010) ANTIHYPERTENSIVE EFFICACY OF VALSARTAN IN SMOKERS VERSUS NON-SMOKERS WITH ARTERIAL HYPERTENSION: THE FIRST RESULTS OF RUSSIAN MULTICENTER OPEN STUDY Abstract  similar documents
V. I. Podzolkov, V. A. Bulatov, A. V. Vigdorchik
"... as patient’s compliance to the mono- or combined valsartan based therapy in smoking vs non-smoking ..."
 
Vol 14, No 3 (2018) ECONOMIC BURDEN OF HYPERCHOLESTEROLEMIA IN THE RUSSIAN FEDERATION Abstract  similar documents
A. V. Kontsevaya, Yu. A. Balanova, A. E. Imaeva, M. B. Khudyakov, O. I. Karpov, O. M. Drapkina
"... required in higher expenditures (outpatients cost treatment expenditures were 2.43 billion RUR, in-patients ..."
 
Vol 14, No 5 (2018) Economic losses due to low coverage of lipid-lowering therapy in patients with cardiovascular diseases in the Russian Federation Abstract  similar documents
Yu. A. Balanova, A. V. Kontsevaya, A. E. Imaeva, O. I. Karpov, M. B. Khudyakov
"... in 2016, including direct costs of the health care system  and indirect economic losses due to premature ..."
 
Vol 11, No 5 (2015) Three-year dynamics and unsolved problems of lipid-lowering therapy Abstract  similar documents
V. A. Sergeeva
"... , smoking, physical inactivity) were present. Lipid-lowering drugs were regularly taken by 26 ..."
 
Vol 9, No 3 (2013) ECONOMIC EVALUATION OF COMBINED THERAPY OF ARTERIAL HYPERTENSION BY MARKOV’S MODELING Abstract  similar documents
N. S. Maksimchuk-Kolobova, E. I. Tarlovskaya, S. V. Malchikova
"... is the most economical variant of pharmacotherapy due to low cost of treatment (16.491.25 RUR per 1 QALY ..."
 
Vol 14, No 4 (2018) Association of Conventional Cardiovascular Risk Factors with Carotid Atherosclerosis Prevalence in General Population Abstract  similar documents
V. S. Kaveshnikov, V. N. Serebryakova, I. A. Trubacheva, S. A. Shalnova
"... studied: age, gender, smoking, low and high density lipoproteins (LDL-C and HDL-C), triglycerides ..."
 
Vol 5, No 5 (2009) THE COMPARATIVE COST-EFFICACY ANALYSIS OF VARIOUS ANTIHYPERTENSIVE THERAPIES Abstract  similar documents
S. V. Malchikova, E. I. Tarlovskaya
"... Aim. To perform the comparative cost-efficacy analysis of various antihypertensive therapies ..."
 
Vol 7, No 2 (2011) COST-EFFECTIVENESS EVALUATION OF PREHOSPITAL THROMBOLYSIS WITH TENECTEPLASE Abstract  similar documents
V. V. Omel'yanovskiy, E. V. Derkach, P. M. Khaylov, S. N. Tereshchenko
"... Aim. To evaluate clinical and cost effectiveness of different reperfusion strategies in myocardial ..."
 
Vol 7, No 2 (2011) SOCIO-ECONOMIC DAMAGE BY ACUTE CORONARY SYNDROME IN RUSSIAN FEDERATION Abstract  similar documents
A. V. Kontsevaya, A. M. Kalinina, I. E. Koltunov, R. G. Oganov
"... . Material and Methods. Direct costs and economic losses associated with ACS were estimated. The structure ..."
 
Vol 7, No 4 (2011) VALUE OF THERAPEUTIC EQUIVALENCE IN SUBSTITUTION OF ORIGINAL DRUG WITH GENERIC BY EXAMPLE OF FOSINIPRIL Abstract  similar documents
N. P. Kutishenko, S. Yu. Martsevich, Zh. D. Kobalava, E. K. Shavarova
"... with arterial hypertension (HT) of 1-2 degrees, and to evaluate the cost effectiveness of original drug ..."
 
Vol 11, No 5 (2015) Cost-effectiveness of new oral anticoagulants in the treatment and secondary prevention of venous thromboembolism Abstract  similar documents
A. V. Rudakova
"... Aim. To assess the cost-effectiveness of apixaban in the treatment and secondary prevention ..."
 
Vol 8, No 1 (2012) ANALYSIS OF COST STRUCTURE FOR PHARMACOTHERAPY OF PATIENTS WITH STABLE ANGINA (THE CASE OF CARDIOLOGY DEPARTMENT OF TVER REGIONAL CLINICAL HOSPITAL) Abstract  similar documents
M. A. Demidova, N. N. Kirilenko
"... Aim. To analyze the cost structure for pharmacotherapy of patients with stable angina (SA ..."
 
Vol 11, No 3 (2015) PREVALENCE OF TYPE D PERSONALITY AND ITS ASSOCIATION WITH CARDIOVASCULAR DISEASES AND THEIR RISK FACTORS ACCORDING TO THE ESSE STUDY CONDUCTED IN KEMEROVO REGION Abstract  similar documents
A. N. Sumin, O. I. Raykh, E. V. Indukaeva, G. V. Artamonova
"... ) and patients without type D personality (n=1379). Arterial hypertension, smoking, diabetes ..."
 
Vol 7, No 5 (2011) ECONOMIC BENEFITS OF LEFT VENTRICULAR HYPERTROPHY REGRESSION IN PATIENTS WITH ARTERIAL HYPERTENSION Abstract  similar documents
E. I. Tarlovskaya, N. S. Maksimchuk, S. V. Malchicova, M. V. Avksentieva, I. E. Sapozhnikova, Y. A. Balandina
"... 516 772.42 RUR for every 1 000 patients. It would reduce the total costs per patient during 10 years ..."
 
Vol 11, No 3 (2015) ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION Abstract  similar documents
A. V. Rudakova
"... of them the cost of anticoagulation therapy was determined on the basis of the average weighted prices ..."
 
Vol 7, No 4 (2011) SPECIAL CONSIDERATIONS REGARDING WARFARIN DOSE TITRATION IN PATIENTS WITH ATRIAL FIBRILLATION DEPENDING ON CLINICAL FACTORS Abstract  similar documents
E. L. Artanova, E. V. Saleeva, I. M. Sokolov, Y. G. Shvarts
"... , obesity , thyroid nodular changes, smoking and amiodarone treatment. ..."
 
Vol 6, No 5 (2010) PHOSPHODIESTERASE-5 INHIBITORS USE IN PATIENTS WITH ERECTILE DYSFUNCTION AND CARDIOVASCULAR DISEASE IN CLINICAL PRACTICE Abstract  similar documents
M. N. Mamedov, G. G. Sharvadze, E. A. Poddubsky, A. K. Ausheva
"... , hypertension, diabetes mellitus), as well as certain risk factors (smoking, alcohol abuse, physical inactivity ..."
 
Vol 6, No 4 (2010) CORRELATIONS OF LOW MOLECULAR WEIGHT PHENOTYPE OF APOPROTEIN(A) AND SERUM LEVEL OF LIPOPROTEIN(A) WITH MULTIFOCAL ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE Abstract  similar documents
O. I. Afanasieva, M. V. Ezhov, M. I. Afanasieva, M. S. Safarova, J. V. Berestetskaya, S. N. Pokrovsky
"... analysis (including sex, age, smoking status, and Lp(a) serum level) only smoking status (β=0.203, p=0 ..."
 
Vol 7, No 6 (2011) EXPERIENCE OF «SCHOOL OF HEALTH» AND A ROLE OF THE GENERAL PRACTITIONER IN THE STRUGGLE WITH RISK FACTORS OF ISCHEMIC HEART DISEASE Abstract  similar documents
N. M. Nurillaeva, A. G. Gadaev
"... in 14.6%, low physical activity in 7.4%, smoking in 6.6%. Conclusion. Organization of the "School ..."
 
Vol 6, No 4 (2010) ECONOMIC EFFICIENCY OF THE IMPLEMENTATION OF THE PROGRAM OF CARDIOVASCULAR DISEASES MULTIFACTORIAL PREVENTION IN THE ORGANIZED COLLECTIVE OF TECHNICAL RESEARCH INSTITUTE Abstract  similar documents
A. V. Kontsevaya, A. M. Kalinina, S. V. Belonosova, J. M. Pozdnjakov, M. B. Khudyakov
"... consultation. Costs associated with cardiovascular diseases and risk factors (medical care consumption ..."
 
Vol 4, No 3 (2008) INFLUENCE OF HEALTH SCHOOL TRAINING OF PATIENTS WITH ISCHEMIC HEART DISEASE ON PHARMACOTHERAPY PROFILE AND COST (АВС/VEN ANALYSIS) Abstract  similar documents
A. V. Kontsevaja, А. М. Kalinina, E. J. Spivak
"... Aim. To study influence of patient training in Health School on pharmacotherapy profile and cost ..."
 
Vol 9, No 4 (2013) COMPARISON OF DIRECT COSTS OF DABIGATRAN AND WARFARIN THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION DURING PREPARATION FOR ELECTIVE CARDIOVERSION IN THE REAL CLINICAL PRACTICE Abstract  similar documents
L. E. Kuvshinova, N. V. Furman, P. V. Dolotovskaya, Ya. P. Dovgalevsky
"... Aim. To compare direct medical costs of dabigatran and warfarin therapy in patients with non ..."
 
Vol 9, No 1 (2013) CLINICAL AND COST EFFECTIVENESS OF PREVENTIVE COUNSELING OF YOUNG PATIENTS WITH ARTERIAL HYPERTENSION IN PRIMARY HEALTH CARE Abstract  similar documents
M. I. Shupina, O. Ju. Korennova, E. N. Loginova
"... Aim. To study clinical and cost effectiveness of training of young patients with arterial ..."
 
Vol 10, No 3 (2014) COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION Abstract  similar documents
A. V. Rudakova, V. A. Parfenov
"... in patients with NVAF in the Russian Federation. Aim. To evaluate the cost-effectiveness ratio of apixaban ..."
 
Vol 8, No 1 (2012) CHANGES IN THE COSTS OF HYPERTENSIVE CRISIS THERAPY DUE TO OPTIMIZATION OF DRUG SUPPLY IN THE PRE-ADMISSION CARE Abstract  similar documents
N. I. Gaponova, N. F. Plavunov, V. L. Baratashvili
"... Aim. To assess the changes in the costs of treatment of patients with hypertensive crisis (HC ..."
 
Vol 13, No 6 (2017) FACTORS INFLUENCING ON THE MORTALITY IN PATIENTS WITH OBLITERATING DISEASES OF LOWER LIMB ARTERIES Abstract  similar documents
A. N. Sumin, M. A. Kosova, Ju. D. Medvedeva, A. V. Shcheglova, O. I. Rajh, S. A. Makarov, G. V. Artamonova, L. S. Barbarash
"... frequent in patients with lethal outcome, they were characterized by a longer smoking experience (17 ..."
 
Vol 14, No 1 (2018) ASSOCIATION OF RISK FACTORS FOR NON-COMMUNICABLE DISEASES WITH HEALTH CARE RESOURCES UTILIZATION AND TEMPORARY DISABILITY ACCORDING TO DATA OF POPULATION STUDY IN RUSSIAN FEDERATION Abstract  similar documents
E. I. Suvorova, S. A. Shalnova, A. V. Kontsevaya, A. D. Deev, A. V. Kapustina, Yu. A. Balanova
"... of participants who call to ambulance increased among smoking men (1,41; p<0,05) and with hyperglycemia (1,38; p<0 ..."
 
Vol 13, No 4 (2017) HEALTHCARE RESOURCES UTILIZATION AND TEMPORARY DISABILITY IN POPULATION AGED 50-64 ACCORDING TO THE EPIDEMIOLOGICAL ESSE-RF STUDY Abstract  PDF (Eng)  similar documents
A. V. Kontsevaya, Yu. A. Balanova, A. E. Imaeva, A. D. Deev, A. V. Kapustina, G. A. Muromtseva, S. E. Evstifeeva, S. A. Shalnova
"... with the probability of hospitalization and/or emergency call. Smoking did not increase the probability ..."
 
Vol 11, No 4 (2015) EVALUATION OF COST-EFFECTIVENESS OF PLATELET REACTIVITY ANALYSIS USING THE VERIFYNOW P2Y12 ASSAY IN PATIENTS AFTER ACUTE CORONARY SYNDROME Abstract  similar documents
A. V. Rudakova, N. V. Lomakin
"... . To assess the cost-effectiveness of VerifyNow P2Y12 platelet reactivity testing in patients after ACS ..."
 
Vol 10, No 1 (2014) ASSOCIATION BETWEEN HEART RATE VARIABILITY AND COMPONENTS OF THE METABOLIC SYNDROME IN WOMEN WITH RHEUMATOID ARTHRITIS Abstract  similar documents
D. S. Novikova, T. V. Popkova, A. N. Gerasimov, A. V. Volkov, E. L. Nasonov
"... , hypertriglyceridemia, hypoalphalipoproteinemia and smoking were found in the correlation analysis. Patients with RA ..."
 
Vol 14, No 2 (2018) PHARMACOECONOMIC ANALYSIS OF CHRONIC HEART FAILURE DRUG THERAPY IN PATIENTS WITH COMORBID CONDITIONS Abstract  similar documents
S. K. Zyryanov, A. E. Cheberda, D. Yu. Belousov
"... of treatment and clinical practice results was built. Cost-effectiveness analysis was done by comparing two ..."
 
Vol 11, No 1 (2015) PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION Abstract  similar documents
A. V. Rudakova
"... of any medical technology is economic value and cost-effectiveness. The objective of this review ..."
 
Vol 11, No 3 (2015) PHARMACOECONOMIC ASPECTS OF THE PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS AFTER LARGE JOINTS REPLACEMENT Abstract  similar documents
A. V. Rudakova
"... or oral anticoagulants that differ significantly in their efficacy, safety and cost of the therapy. Aim ..."
 
Vol 8, No 1 (2012) PHARMACOECONOMIC EVALUATION OF DABIGATRAN VS WARFARIN IN CARDIOVASCULAR EVENTS PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION Abstract  similar documents
Yu. B. Belousov, V. Yu. Mareev, I. S. Yavelov, D. Yu. Belousov
"... the cost-effectiveness of dabigatran etexilate versus warfarin prescribed in “real-world” settings from ..."
 
Vol 14, No 4 (2018) Differences in the Incidence of Major Risk Factors in Patients with Ischemic or Hemorrhagic Stroke in the Siberian Population Abstract  similar documents
S. Yu. Nikulina, A. A. Chernova, D. A. Nikulin, V. A. Shulman, S. V. Prokopenko, I. M. Platunova, O. V. Marilovceva, I. I. Lebedeva, A. A. Semenchukov, D. A. Yakovleva, V. N. Maksimov, A. V. Kuskaeva
"... among them. Smoking was found in 22 (78.6%) patients in this group. Conclusion. Improvement ..."
 
Vol 14, No 5 (2018) Short Term Comparison Between Safety and Efficacy of Rosuvastatin 40 mg and Atorvastatin 80 mg in Patients with Acute Coronary Syndrome Abstract  PDF (Eng)  similar documents
Sh. A. Mostafa, Kh. Elrabat, M. Mahrous, M. Kamal
"... , smoking and obesity), echocardiography (end-diastolic volume, end-systolic volume and ejection fraction ..."
 
Vol 8, No 6 (2012) ASSESSMENT OF DIABETES RISK IN MEN WITH DIFFERENT LEVELS OF CARDIOVASCULAR RISK Abstract  similar documents
M. N. Kovrigina, M. N. Mamedov
"... . Material and methods. Men (n=378) with one or more CV risk factors (hypertension of stage 1–3, smoking ..."
 
Vol 13, No 4 (2017) CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND ARTERIAL HYPERTENSION: VASCULAR WALL AS THE TARGET ORGAN IN COMORBID PATIENTS Abstract  similar documents
N. A. Karoli, A. P. Rebrov
"... were associated with smoking status (r=0.61, p<0.01), severity of bronchial obstruction (r=-0.49, p<0 ..."
 
Vol 4, No 5 (2008) CARDIOVASCULAR RISK IN PATIENTS WITH ANKYLOSING SPONDYLITIS: THE ROLE OF SYSTEMIC INFLAMMATION AND ENDOTHELIAL DYSFUNCTION Abstract  similar documents
D. A. Poddubnyy, A. P. Rebrov
"... cardiovascular risk factors (smoking, hyper- and dislipoproteinemia, body overweight, heredity and diabetes ..."
 
Vol 10, No 2 (2014) PRIMARY PREVENTION OF MYOCARDIAL INFARCTION IN MIDDLE-AGED MALES (15-YEAR FOLLOW-UP): CLINICAL AND ECONOMIC ASPECTS OF THE PROBLEM Abstract  PDF (Eng)  similar documents
A. M. Kalinina, A. V. Kontsevaya
"... . Cost-effectiveness of primary prevention, including the one of MI, has been conclusively showed ..."
 
Vol 13, No 5 (2017) IS IT POSSIBLE TO IMPROVE THE ADHERENCE TO TREATMENT OF HYPERTENSION AND DYSLIPIDEMIA IN PATIENTS WITHOUT CLINICAL MANIFESTATIONS OF ATHEROSCLEROSIS? Abstract  similar documents
A. А. Sarycheva, D. V. Nebieridze, T. V. Kamyshova
"... in the case of achieving target levels of blood pressure (BP) and total cholesterol, smoking cessation ..."
 
Vol 13, No 6 (2017) HEART RATE AND ITS ASSOCIATION WITH THE MAIN RISK FACTORS IN THE POPULATION OF MEN AND WOMEN OF WORKING AGE Abstract  similar documents
S. А. Shalnov, A. D. Deev, O. A. Belova, Yu. I. Grinshtein, D. V. Duplyakov, A. Yu. Efanov, E. V. Indukaeva, N. V. Kulakova, R. A. Libis, S. V. Nedogoda, O. P. Rotar, G. V. Tolparov, I. A. Trubacheva, T. M. Chernykh, A. A. Shabunova, S. A. Boytsov
"... , elevated levels of blood pressure, triglycerides, glucose and CRP, but not education, smoking and alcohol ..."
 
Vol 9, No 1 (2013) OUTPATIENT REGISTER OF CARDIOVASCULAR DISEASES IN THE RYAZAN REGION (RECVASA): PRINCIPAL TASKS, EXPERIENCE OF DEVELOPMENT AND FIRST RESULTS Abstract  PDF (Eng)  similar documents
S. A. Boytsov, S. S. Yakushin, S. Yu. Martsevich, M. M. Lukyanov, N. N. Nikulina, A. V. Zagrebelny, A. N. Vorobyov, K. G. Pereverseva, E. A. Pravkina, A. D. Deev, E. Yu. Andreenko, A. I. Ershova, A. N. Meshkov, R. P. Myasnikov, S. E. Serdyuk, М. S. Kharlap
"... .9%) patients. 770 (77%) patients were assessed on their total cholesterol level; smoking status and family ..."
 
Vol 10, No 1 (2014) MULTIFACTOR PRIMARY PREVENTION OF ISCHEMIC HEART DISEASE IN MIDDLE-AGED MEN AND ITS EFFICACY (10-YEAR FOLLOW-UP) Abstract  PDF (Eng)  similar documents
A. M. Kalinina
"... , hypercholesterolemia, overweight, smoking, low physical activity) in the group 1 lasted for 5 years; the whole period ..."
 
Vol 14, No 5 (2018) Basic Anthropometric Indices and Diabetes Mellitus Type 2 in Russian Population Abstract  similar documents
O. M. Drapkina, R. N. Shepel, S. A. Shalnova, A. D. Deev, Yu. A. Balanova, S. E. Evstifeeva, Yu. V. Zhernakova, A. E. Imaeva, A. V. Kapustina, G. A. Muromtseva, O. P. Rotar, E. V. Shlyakhto, S. A. Boytsov
"... diabetes were analyzed: age; sex; anthropometric indicators: height, weight, WC; smoking status  (“never ..."
 
Vol 6, No 1 (2010) THE BISOPROLOL — A HIGH SELECTIVE BETA-BLOCKER ACCORDING TO EVIDENCE BASED MEDICINE Abstract  similar documents
Yu. V. Lukina, S. Yu. Martsevich
"... ) are presented. Implementation of bisoprolol generics as well as bisoprolol usage in smoking cardiovascular ..."
 
Vol 12, No 1 (2016) Pharmacoeconomic analysis of heart rate slowing drugs in patients with ischemic heart disease Abstract  similar documents
E. I. Tarlovskaya, T. I. Chudinovskikh
"... Aim. To compare the efficacy and cost/effectiveness ratio of the original and generic bisoprolol ..."
 
Vol 9, No 1 (2013) PHARMACOEPIDEMIOLOGICAL AND PHARMACOECONOMIC STUDIES OF ANTIHYPERTENSIVE TREATMENT IN RUSSIA. Analytical Review Abstract  similar documents
T. S. Romanenko, A. V. Kontsevaya, S. V. Fitilev
"... therapy, conducted during the last decades inRussia. Despite the increased interest to the issue of cost ..."
 
Vol 3, No 5 (2007) RENAL HEMODYNAMICS AND GLOMERULAR FILTRATION RATE IN MEN AND WOMEN WITH ARTERIAL HYPERTENSION AT THE AGE OF 40-60 YEARS Abstract  similar documents
I. G. Fomina, A. E. Bragina, N. E. Gaydamakina, J. N. Salimzhanova
"... not differ in control group. Positive correlation  r=0,61; p<0,05) between GGFR and a tobacco smoking ..."
 
Vol 9, No 3 (2013) ANTIHYPERTENSIVE EFFICACY AND INFLUENCE ON SEXUAL FUNCTION OF VALSARTAN AND VALSARTAN AND HYDROCHLOROTHIAZIDE COMBINATION IN SMOKERS VERSUS NON-SMOKERS WITH ARTERIAL HYPERTENSION Abstract  similar documents
V. I. Podzolkov, A. V. Vigdorchik
"... was observed in smoking and non-smoking patients (37.4/17.8 and 36.7/16.5 mm Hg respectively, р<0.01 vs ..."
 
Vol 11, No 6 (2015) Clinical and economic analysis of the use of apixaban for the treatment of venous thromboembolic events Abstract  similar documents
O. V. Shatalova
"... of the health care system. The cost analysis, "cost-effectiveness" analysis, "impact on the budget” analysis ..."
 
Vol 5, No 3 (2009) CLINICAL AND ECONOMICAL RATIONALES OF CARDIOVASCULAR RISK EVALUATION AT WORKPLACE Abstract  similar documents
A. V. Kontsevaya, A. M. Kalinina, Yu. M. Pozdnyakov, S. V. Belonosova, M. B. Khudyakov
"... (with estimation of the total costs, costs for one studied person and costs for revealing of one person needed ..."
 
Vol 13, No 1 (2017) CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION Abstract  similar documents
S. V. Nedogoda, I. N. Barykina, A. S. Salasiuk, V. O. Smirnova
"... Aim. To compare cost-effectiveness of the use of direct factor Xa inhibitors rivaroxaban ..."
 
Vol 3, No 4 (2007) THE ALGORITHMIC MODEL OF LABORATORY DIAGNOSTICS OPTIMIZATION Abstract  similar documents
G. I. Nazarenko, O. V. Andropova
"... of algorithmic approach is able to optimize diagnostics and its costs. Various algorithmic models, their features ..."
 
Vol 6, No 2 (2010) VALSARTAN IN EVERYDAY CLINICAL PRACTICE IN RUSSIA: ANTIHYPERTENSIVE EFFICACY AND INFLUENCE ON SEXUAL FUNCTION IN PATIENTS WITH ARTERIAL HYPERTENSION Abstract  similar documents
V. I. Podzolkov, V. A. Bulatov, A. V. Vigdorchik
"... was allowed. Results. Significant similar decrease of SBP and DBP was observed in smoking and non-smoking ..."
 
Vol 7, No 1 (2011) THE CHOICE OF THE DRUG AMLODIPINE FOR THE HYPERTENSION TREATMENT FROM THE STANDPOINT OF ECONOMIC FEASIBILITY Abstract  similar documents
S. Yu. Martsevich, N. A. Dmitrieva, A. D. Deev, Yu. V. Lukina, L. A. Sokolova, V. V. Yakusevich
"... Aim. Тo compare the cost-effectiveness of antihypertensive therapy based on a generic and original ..."
 
Vol 8, No 2 (2012) PRELIMINARY RESULTS OF COMPARATIVE PHARMACOECONOMIC PROSPECTIVE STUDY OF DIFFERENT THERAPIES OF ARTERIAL HYPERTENSION Abstract  similar documents
E. I. Tarlovskaya, N. S. Maksimchuk, S. V. Malchikova, M. V. Avksentieva
"... (LVMI) were considered. Cost-effectiveness method of analysis was used. Results. In V/A group 75 ..."
 
Vol 6, No 4 (2010) PHARMACOECONOMIC ANALYSIS OF CARVEDILOL THERAPY IN PATIENTS WITH ARTERIAL HYPERTENSION AND METABOLIC RISK FACTORS (ACCORDING TO THE CAMELLIA STUDY) Abstract  similar documents
S. Y. Martsevich, N. P. Kutishenko, A. D. Deev, S. A. Shalnova, R. G. Oganov
"... Aim. To perform cost-effectiveness analysis of 24 weeks antihypertensive therapy based ..."
 
Vol 7, No 5 (2011) COMPARATIVE EFFICACY AND SAFETY OF HYPOLIPIDEMIC THERAPY WITH GENERIC AND ORIGINAL MEDICINAL PRODUCTS OF SIMVASTATIN Abstract  similar documents
E. I. Tarlovskaya, Yu. A. Balandina, I. E. Sapozhnikova, N. S. Maksimchuk
"... , creatine phosphokinase were evaluated every 4 weeks. Cost-effectiveness ratio was calculated. Results. 11 ..."
 
Vol 5, No 4 (2009) TO THE 110-TH ANNIVERSARY OF RENIN FINDING. FIGHT OF TITANS: ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND SARTANS Abstract  similar documents
L. N. Malay, A. N. Miroshnichenko, B. V. Sharykin, V. V. Konurovsky
"... , treatment costs and safety). The place of ACE inhibitors and ARB in modern therapy of cardiovascular ..."
 
Vol 10, No 4 (2014) PHARMACOECONOMIC ANALYSIS OF ANTIHYPERTENSIVE DRUG COMBINATIONS USE Abstract  similar documents
E. I. Tarlovskaya, Y. A. Balandina, N. S. Maximchuk-Kolobova
"... without ischemic heart disease (n=56) were included into the study. Blood pressure (BP) dynamics and cost ..."
 
Vol 8, No 2 (2012) THE "NEW" DRUG CLASSES IN THE TREATMENT OF CHRONIC HEART FAILURE AND THEIR EVIDENCE BASE Abstract  similar documents
S. N. Tereshchenko, I. V. Zhirov, A. G. Kochetov, O. V. Uspenskaya
"... to treatment, induces additional costs or may be a reason of new side effects. Additional (to standard therapy ..."
 
Vol 14, No 2 (2018) ECONOMIC BURDEN OF CARDIOVASCULAR DISEASES IN THE RUSSIAN FEDERATION IN 2016 Abstract  PDF (Eng)  similar documents
A. N. Kontsevaya, O. M. Drapkina, Yu. A. Balanova, A. E. Imaeva, E. I. Suvorova, M. B. Khudyakov
"... (RF) in 2016, including the direct costs and the economic losses caused by reduced productivity ..."
 
Vol 4, No 4 (2008) PRIORITIES IN CONCEPT OF CARDIOVASCULAR RISK FACTORS IN IRRADIATED PATIENTS AT DISTANT PERIOD AFTER CHERNOBYL NUCLEAR DISASTER BASED ON PROSPECTIVE COHORT DATA Abstract  similar documents
R. G. Oganov, V. S. Sherashov, N. V. Sherashova, M. V. Sherashova, S. K. Kukushkin, O. G. Rudakova, E. A. Zhavoronkova
"... of standard questionnaires, social and demographic description, education, family status, smoking and alcohol ..."
 
Vol 10, No 6 (2014) THE PREVALENCE OF ELEVATED LEVELS OF C-REACTIVE PROTEIN AND ITS ASSOCIATION WITH TRADITIONAL RISK FACTORS AND MORBIDITY AMONG RESIDENTS OF THE RUSSIAN FEDERATION (ACCORDING TO THE ESSE-RF STUDY) Abstract  similar documents
S. E. Evstifeeva, S. A. Shalnova, A. D. Deev, T. M. Gatagonova, A. Yu. Efanov, Yu. V. Zhernakova, V. A. Il'in, A. O. Konradi, V. A. Metelskaya, E. V. Oschchepkova, S. V. Romanchuk, O. P. Rotar, I. A. Trubacheva, E. V. Shlyakhto, S. A. Boytsov
"... , and smoking population of Russians. After the multivariate adjustment there remained significant associations ..."
 
Vol 14, No 2 (2018) NEW DIRECT ORAL ANTICOAGULANTS FOR TREATMENT OF PATIENTS WITH ATRIAL FIBRILLATION IN REAL-WORLD SETTING Abstract  similar documents
Zh. D. Kobalava, S. V. Villevalde, A. A. Shavarov
"... is easy to follow and well accepted by patients despite of twice-daily dosing regimen. Healthcare cost ..."
 
Vol 13, No 2 (2017) THESES OF PSYCHOSOMATIC MEDICINE Abstract  similar documents
F. I. Belyalov
"... , increase healthcare costs. Antidepressants decrease severity of anxiety and depression, as well as diminish ..."
 
Vol 1, No 1 (2005) ASSESSMENT OF QUALITY OF GENERICS IN CARDIOLOGY: REALITY AND POSSIBILITIES Abstract  similar documents
V. V. Yakusevich
"... it possible to decrease the costs of treatment. From the other side with the advent of big number of copies ..."
 
Vol 10, No 2 (2014) EVALUATION OF ATRIAL CONTRACTILE FUNCTION DISORDERS AND FIBROSIS AS PREDICTORS OF CHRONIC HEART FAILURE Abstract  similar documents
O. M. Drapkina, E. V. Cherkunova
"... Chronic heart failure (CHF) is a major health problem in many countries now, and the cost ..."
 
Vol 6, No 6 (2010) EFFICACY AND SAFETY OF SINUS RHYTHM RESTORATION WITH AMIODARONE AND PROPAFENONE IN OUTPATIENTS, ECONOMIC ASPECTS (BASED ON DATA OF N.A. SEMASHKO NORTHERN MEDICAL CLINICAL CENTER) Abstract  similar documents
T. A. Istomina, E. V. Serdechnaya, L. A. Kulminskaya, B. A. Tatarskiy, E. V. Kazakevich, V. L. Lipskiy, S. I. Martyushov
"... ), and amiodarone 600-800 mg daily. The cost/effectiveness ratio (CER) was estimated. This ratio shows the cost ..."
 
Vol 14, No 2 (2018) RATIONAL PHARMACOTHERAPY IN CARDIOLOGY: FROM MINIMIZATION OF EXPENSES TO EFFECTIVE MANAGEMENT Abstract  similar documents
N. A. Nikolayev, Yu. P. Skirdenko, S. S. Bunova, A. V. Ershov
"... than the class or cost of medicines, the original or generic nature of the drugs, or their dosage ..."
 
Vol 4, No 5 (2008) CLINICAL AND ECONOMICAL ASSESSMENTS OF METOPROLOL TARTRATE/SUCCINATE USAGE IN PATIENTS WITH ISCHEMIC HEART DISEASE Abstract  similar documents
M. V. Soura
"... ’s comparative cost analysis on metoprolol tartrate (Betaloc) and metoprolol succinate (Betaloc ZOK) usage ..."
 
Vol 3, No 5 (2007) CLINICAL AND PHARMACOKINETIC EQUIVALENCE OF ORIGINAL AND GENERIC AMLODIPINE IN PATIENTS WITH MILD-TO-MODERATE ARTERIAL HYPERTENSION Abstract  similar documents
N. A. Belolipetskiy, S. N. Tolpygina, J. B. Zverkov, V. V. Pisarev, I. E. Koltunov, V. G. Belolipetskaya, S. J. Martsevich
"... Amlorus and Norvasc, respectively. Cost of Amlorus therapy per patient was 221 rbl/month in comparison ..."
 
Vol 4, No 1 (2008) PHARMACOEPIDEMIOLOGICAL STUDY OF DOCTORS HABITS IN PRESCRIPTIONS OF ANTIHYPERTENSIVE DRUGS IN TOWN OF OREL Abstract  similar documents
G. I. Shvets, S. V. Povetkin
"... % of doctors prescribed pharmacotherapy, which cost 100 to 500 rubles per months. Not rational combinations ..."
 
Vol 7, No 6 (2011) COMPARATIVE EFFICACY OF COMBINED ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH MODERATE ARTERIAL HYPERTENSION ACCOMPANIED BY TYPE 2 DIABETES Abstract  similar documents
E. I. Tarlovskaya, Yu. A. Balandina, I. E. Sapozhnikova, N. S. Maksimchuk
"... ) and microalbuminuria (MAU) and to calculate cost-effectiveness ratio (CER). Material and methods. Patients (n=75 ..."
 
Vol 14, No 2 (2018) WHAT DO PATIENTS WITH ATRIAL FIBRILLATION KNOW ABOUT STROKE AND SYSTEMIC EMBOLISM PREVENTION? DATA OF THE PRIMA-TERRA REGISTRY Abstract  similar documents
R. М. Linchak, O. G. Kompaniyets, A. M. Nedbaykin
"... . The main reason limiting the widespread use of NOACs is the high cost of these drugs. Conclusion ..."
 
Vol 14, No 4 (2018) Physician’s Adherence to Clinical Guidelines for in-Hospital Anticoagulant Prescribing Abstract  similar documents
A. A. Chernov, E. V. Kleymenova, D. A. Sychev, L. P. Yashina, M. D. Nigmatkulova, V. A. Otdelenov, S. A. Payushchik
"... » group direct cost for inpatient AC therapy was significantly higher than in «adherent» group 4041 rubles ..."
 
Vol 14, No 6 (2018) Availability and Affordability of Medicines for the Treatment of Cardiovascular Diseases in Pharmacies in Six Regions of the Russian Federation Abstract  PDF (Eng)  similar documents
A. E. Imaeva, Yu. A. Balanova, A. V. Kontsevaya, A. V. Kapustina, D. V. Duplyakov, O. H. Malysheva, I. V. Osipova, T. A. Petrichko, G. I. Kropanin, R. A. Kasimov, D. A. Leon, M. McKee
"... analyzing the cost of drugs in licensed pharmacies, it was found that drugs containing furosemide ..."
 
Vol 8, No 2 (2012) COMPARISON OF PHARMACOKINETICS AND PHARMACODYNAMICS OF THE ORIGINAL AND GENERIC ENALAPRIL IN THE ELDERLY PATIENTS WITH ARTERIAL HYPERTENSION Abstract  similar documents
O. P. Bobrova, M. M. Petrova
"... of cost minimization analysis. Results. Original enalapril dose necessary to achieve the target blood ..."
 
Vol 5, No 4 (2009) CLINICO-ECONOMICAL ANALYSIS OF THE TREATMENT EFFICACY IN PATIENTS WITH ARTERIAL HYPERTENSION OF 1-2 DEGREES Abstract  similar documents
L. A. Haisheva, S. V. Shlyk, T. Y. Bykovskaya
"... was performed according to “cost-efficacy” approach at the end of 3 month therapy. Results. About 50 ..."
 
Vol 6, No 2 (2010) EVALUATION BY PRACTICING DOCTORS OF THE MODERN PHARMACOTHERAPY POSSIBILITIES IN PATIENTS WITH ISCHEMIC HEART DISEASE. RESULTS OF DOCTOR INTERVIEW IN MOSCOW AND VORONEZH Abstract  similar documents
S. Yu. Martsevich, L. Yu. Drozdova, Yu. V. Lukina, N. V. Sinyagina, T. G. Kheliya
"... , respectively, considered high cost of statins as the main limit for its implementation. Conclusion. On one ..."
 
Vol 4, No 3 (2008) ESTIMATION OF CLINICAL AND PHARMACOKINETIC EQUIVALENCE OF ORIGINAL AND GENERIC CARVEDILOLS IN PATIENTS WITH HYPERTENSION OF 1-2 GRADES Abstract  similar documents
E. I. Bambysheva, S. N. Tolpygina, D. F. Guranda, I. E. Koltunov, V. G. Belolipetskaja, S. J. Martsevich
"... carvedilol has lower cost of treatment than this in original carvedilol. ..."
 
Vol 12, No 3 (2016) LOW ADHERENCE TO TREATMENT AFTER MYOCARDIAL INFARCTION: CAUSES AND WAYS OF ADJUSTMENT CONSIDERING PSYCHO-EMOTIONAL STATE OF PATIENTS Abstract  PDF (Eng)  similar documents
E. A. Kuzheleva, K. N. Borel', A. A. Garganeeva
"... 's prescriptions (14%); a large number of prescribed drugs (12%); high cost of drugs (4%). The structure ..."
 
Vol 11, No 4 (2015) MULTI-CHANNEL VOLUME SPHYGMOGRAPHY IN CARDIOANGIOLOGICAL SCREENING OF THE ADULT POPULATION Abstract  similar documents
R. A. Khokhlov, N. I. Ostroushko, A. E. Gaydashev, D. V. Kirsanov, N. M. Akhmedzhanov
"... be regarded as the basis for low-cost and efficient system of cardioangiological screening. ..."
 
Vol 9, No 5 (2013) ASSESSING FACTORS THAT FORM PATIENT’S ATTITUDE TO TREATMENT PRECEDING HOSPITALIZATION FOR ACUTE CORONARY SYNDROM (DATA OF QUESTIONNAIRE WITHIN THE LIS REGISTER) Abstract  PDF (Eng)  similar documents
Yu. V. Lukina, M. L. Gynzburg, V. P. Smirnov, S. Yu. Martsevich, N. P. Kutishenko, A. V. Fokina, E. V. Daniels
"... the importance of lowering drug costs. 11 patients of 272 respondents demanded more care from their doctor; 4 ..."
 
1 - 96 of 96 Items

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)